Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash flows from operating activities
Net loss	$ (865,970)	$ (3,709,899)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	52,681	44,764
Change in fair value of warrant liability	(37,311)	562,918
Changes in operating assets and liabilities:
Advances on research and development contract services		267,789
Prepaid insurance	99,254	93,702
Accounts payable and accrued expenses	(137,076)	41,618
Research and development contract liabilities		1,349,116
Accrued legal settlement	(414,989)
Net cash used in operating activities	(1,303,411)	(1,349,993)
Cash flows from financing activities
Proceeds from sale of common stock units in public offering, net of offering costs	1,504,476
Net cash provided by financing activities	1,504,476
Net increase (decrease) in cash	201,065	(1,349,993)
Cash, beginning of period	3,026,569	7,538,312
Cash, end of period	3,227,634	6,188,319
Supplemental information
Income taxes paid
Noncash investing and financing activities
Options issued to settle accrued bonus	$ 77,400